This study assessed DMARD switching, cycling, adherence, and persistence at an outpatient rheumatology clinic with an integrated health-system specialty pharmacy.

This study evaluates rates and reasons for switching and cycling in patients with RA. The most common reasons for switching and cycling were loss of efficacy, no efficacy and intolerable adverse effects.

This study evaluated rates of adherence to biologic DMARDS, measured by proportion of days covered (PDC), across 20 health-system specialty pharmacies through the Health-System Specialty Pharmacy Outcomes Research Consortium. The final median PDC after accounting for appropriate gaps in therapy was high at 95% (IQR, 0.87-0.99), demonstrating the benefits of health-system specialty pharmacies in helping patients with RA remain on effective therapies.